Oncology Department, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Nanjing, 210029, Jiangsu province, China.
Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, 60126, Ancona, Italy.
BMC Complement Med Ther. 2020 Nov 10;20(1):337. doi: 10.1186/s12906-020-03135-8.
The exploration of new therapeutic agents targeting 5-Fu resistance may open a new opportunity to gastric cancer treatment. The objective is to establish a 5-Fu resistant gastric cancer cell line and observe the effect of Jianpi Yangwei decoction (JPYW) on its apoptosis and drug-resistance related proteins.
MTT assay was used to measure the effect of JPYW on the BGC823 cells proliferation, and the apoptosis was observed by flow cytometry and Hoechst fluorescence staining. The BGC823 xenograft tumor nude mice models were established, the apoptosis was detected by Tunel method. BGC-823/5-Fu was established by repeated low-dose 5-Fu shocks, the drug resistance index and proliferation were detected by the MTT assay; MDR1 mRNA was detected by real-time RT-PCR; Western blot was used to detect the ratio of p-AKT to AKT; The BGC823/5-Fu xenograft tumor nude mice models were established and apoptosis was measured. The expressions of MRP1, MDR1, ABCG2, AKT, p-AKT, caspase-3 and bcl-2 were detected by immunohistochemistry and the AKT mRNA expression was detected by real-time RT-PCR.
JPYW induced apoptosis in BGC823 cells; Drug-resistant cell line BGC-823/5-Fu was sucessfully established; JPYW induced apoptosis of BGC823/5-Fu cells, down-regulated the expression of MRP1, MDR1 and ABCG2 in vitro and in vivo, and further decreased MDR1 expression when combined with pathway inhibitor LY294002 (P < 0.05); JPYW down-regulated the ratio of p-AKT to AKT in vitro in a dose-dependent manner, the same as after the combination with LY294002 (P < 0.05).
JPYW can induce apoptosis of BGC823 and BGC823/5-Fu cells, and down-regulate the expression of MDR1, MRP1, ABCG2 in vitro and in vivo. Its in vitro effect is related to the PI3K/AKT signaling pathway.
探索针对 5-Fu 耐药的新型治疗药物可能为胃癌治疗开辟新的机会。目的是建立 5-Fu 耐药胃癌细胞系,并观察健脾养胃汤(JPYW)对其凋亡和耐药相关蛋白的影响。
MTT 法检测 JPYW 对 BGC823 细胞增殖的影响,流式细胞术和 Hoechst 荧光染色观察细胞凋亡。建立 BGC823 裸鼠异种移植瘤模型,Tunel 法检测细胞凋亡。通过反复低剂量 5-Fu 冲击建立 BGC-823/5-Fu 耐药细胞系,MTT 法检测耐药指数和增殖;实时 RT-PCR 检测 MDR1mRNA;Western blot 检测 p-AKT/AKT 比值;建立 BGC823/5-Fu 裸鼠异种移植瘤模型,检测细胞凋亡。免疫组化法检测 MRP1、MDR1、ABCG2、AKT、p-AKT、caspase-3 和 bcl-2 的表达,实时 RT-PCR 检测 AKT mRNA 的表达。
JPYW 诱导 BGC823 细胞凋亡;耐药细胞系 BGC-823/5-Fu 成功建立;JPYW 诱导 BGC823/5-Fu 细胞凋亡,下调 MRP1、MDR1 和 ABCG2 的表达,体内外进一步降低 MDR1 表达,与通路抑制剂 LY294002 联合应用时差异有统计学意义(P<0.05);JPYW 呈剂量依赖性下调体外 p-AKT/AKT 比值,与 LY294002 联合应用时差异有统计学意义(P<0.05)。
JPYW 可诱导 BGC823 和 BGC823/5-Fu 细胞凋亡,下调 MRP1、MDR1、ABCG2 的表达,体内外均有作用。其体外作用与 PI3K/AKT 信号通路有关。